Want to see CH:KURN full AI Analyst Report?
Top Page
Kuros Biosciences
(KURN)
Select Model
Select Model
Rating:58Neutral
Price Target:
CHF22.00
▼(-21.88% Downside)
Action:Reiterated
Date:07/09/26
The score is primarily supported by improving financial performance (rapid revenue growth, strong margins, and low leverage), but is held back by weak cash flow conversion in 2025 and a very expensive valuation (high P/E). Technical indicators are neutral-to-mixed and do not materially offset these risks.
Positive Factors
Revenue Growth
Sustained, multi-year top-line expansion demonstrates successful commercial traction for MagnetOs and a scalable revenue model. Durable revenue growth increases runway for reinvestment in sales, clinical evidence and geographic expansion, underpinning longer-term market penetration.
Negative Factors
Weak Cash Conversion
Despite accounting profitability in 2025, negative operating and free cash flow signal working-capital strain or investment outlays that erode liquidity. Persistent negative cash conversion increases reliance on external funding and could constrain marketing or clinical investment needed to sustain growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained, multi-year top-line expansion demonstrates successful commercial traction for MagnetOs and a scalable revenue model. Durable revenue growth increases runway for reinvestment in sales, clinical evidence and geographic expansion, underpinning longer-term market penetration.
Read all positive factors
Kuros Biosciences (KURN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF834.95M
Dividend YieldN/A
Average Volume (3M)128.87K
Price to Earnings (P/E)501.9
Beta (1Y)1.42
Revenue Growth59.85%
EPS GrowthN/A
CountryCH
Employees178
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.04
Shares Outstanding39,458,786
10 Day Avg. Volume110,510
30 Day Avg. Volume128,868
Financial Highlights & Ratios
PEG Ratio-3.21
Price to Book (P/B)15.78
Price to Sales (P/S)8.71
P/FCF Ratio-439.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF35.00Price Target Upside24.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.28
Revenue Forecast (FY)CHF201.30M
Kuros Biosciences Business Overview & Revenue Model
Company Description
Kuros Biosciences AG functions as a biopharmaceutical enterprise, dedicated to both the development and market introduction of advanced therapeutic solutions for tissue regeneration and bone repair. Its operations span across the United States, th...
How the Company Makes Money
Kuros primarily makes money by selling its synthetic bone graft products (notably MagnetOs) to hospitals and surgical centers for use in procedures such as spinal fusion and other bone repair applications. Revenue is generated from product sales v...
Kuros Biosciences Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
82
Very Positive
Cash Flow
46
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 121.30M | 75.56M | 33.56M | 17.99M | 13.81M |
| Gross Profit | 104.79M | 62.03M | 23.94M | 10.77M | 10.07M |
| EBITDA | 10.13M | -561.00K | -6.84M | -8.84M | -5.29M |
| Net Income | 2.12M | -3.72M | -13.73M | -14.60M | -7.54M |
Balance Sheet | |||||
| Total Assets | 107.21M | 84.54M | 71.46M | 82.95M | 91.34M |
| Cash, Cash Equivalents and Short-Term Investments | 15.66M | 17.46M | 14.21M | 24.07M | 28.62M |
| Total Debt | 3.94M | 1.79M | 2.14M | 1.91M | 8.93M |
| Total Liabilities | 40.28M | 25.79M | 14.75M | 14.09M | 14.36M |
| Stockholders Equity | 66.93M | 58.75M | 56.71M | 68.86M | 76.98M |
Cash Flow | |||||
| Free Cash Flow | -2.40M | 2.03M | -9.17M | -7.75M | -5.83M |
| Operating Cash Flow | -377.87K | 3.14M | -8.84M | -7.35M | -5.45M |
| Investing Cash Flow | -2.03M | -1.11M | -326.00K | -400.00K | -374.00K |
| Financing Cash Flow | 1.17M | 1.34M | -171.00K | 3.22M | 6.08M |
Kuros Biosciences Technical Analysis
Neutral
28.16
Price Trends
20.03
Positive
22.37
Negative
25.13
Negative
Market Momentum
0.01
Negative
62.99
Neutral
82.52
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:KURN, the sentiment is Neutral. The current price of 28.16 is above the 20-day moving average (MA) of 19.27, above the 50-day MA of 20.03, and above the 200-day MA of 25.13, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 62.99 is Neutral, neither overbought nor oversold. The STOCH value of 82.52 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CH:KURN.
Kuros Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | CHF667.20M | 20.78 | ― | ― | 11.43% | -48.80% | |
58 Neutral | CHF834.95M | 501.88 | -7.82% | ― | 59.85% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | CHF245.92M | -19.38 | ― | ― | -63.05% | -187.61% | |
48 Neutral | CHF1.67B | -6.74 | ― | ― | 35.80% | 24.01% | |
44 Neutral | CHF224.00M | -4.12 | -301.13% | ― | 97.32% | -11.07% | |
43 Neutral | CHF129.60M | -2.06 | -51.05% | ― | -100.00% | 9.23% |
* Healthcare Sector Average
CH:KURN
Kuros Biosciences
21.44
-6.84
-24.19%
CH:MOLN
Molecular Partners AG
3.23
0.34
11.80%
CH:BSLN
Basilea Pharmaceutica
54.70
6.50
13.49%
CH:IDIA
Idorsia Ltd
6.20
3.86
164.39%
CH:NWRN
Newron Pharmaceuticals SpA
11.80
4.63
64.57%
CH:SANN
Santhera Pharmaceuticals Holding
15.22
3.02
24.75%
Kuros Biosciences Corporate Events
Kuros Biosciences posts 51% Q1 sales surge on MagnetOs growth and manufacturing expansion
Apr 14, 2026
Kuros Biosciences reported a 51% year-on-year increase in total product sales to USD 43.4 million for the first quarter of 2026, driven almost entirely by MagnetOs, which also grew 51% to USD 42.9 million. EBITDA improved to USD 2.9 million and ad...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.